

ChemComm

Accepted Manuscript



This article can be cited before page numbers have been issued, to do this please use: N. S. Simpkins, G. R. Peczkowski, P. Craven and D. Stead, *Chem. Commun.*, 2019, DOI: 10.1039/C8CC10263E.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [author guidelines](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the ethical guidelines, outlined in our [author and reviewer resource centre](#), still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

COMMUNICATION

2,7-Diazabicyclo[2.2.1]heptanes: Novel Asymmetric Access and Controlled Bridge-Opening

 Gary R. Peczkowski,^a Philip G. E. Craven,^a Darren Stead^b and Nigel S. Simpkins^{*a}

 Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/


Organocatalysed asymmetric Michael additions of substituted triketopiperazines to enones afford products in high yield and enantiomeric ratio (er). Further modification delivers products possessing natural product (NP) scaffolds including diazabicyclo[2.2.1]heptane, prolinamide and harmicine.

For many years natural products have provided organic chemists with a multitude of synthetically challenging architectures, providing the stimulus for the development of new synthetic methods and strategies. An additional driving force in this field is provided by the diverse biological activities inherent in many natural products. The fact that around 30% of small molecule drugs developed the last 30 years are either natural products, or their close relatives, is ample testament to the significance of this area.^{1,2}

Traditionally, natural product synthesis is the exploration of a route towards a singular target compound³ and with rapid access in mind, many research groups compete for the shortest linear sequence.^{4,5} However, this approach often overlooks any potentially rewarding analogues or family members.⁶ Therefore, a route in which multiple interesting scaffolds may be accessed from a common motif is highly desirable.^{7,8}

In this report we describe how our newly developed asymmetric access to triketopiperazines (TKPs) can be utilised in this way to gain access to several interesting natural product-like motifs, as illustrated in Scheme 1.

We conceived that structures including various diazabicyclo[2.2.1]heptane core structures and proline amides would be available via initial asymmetric Michael addition of a TKP, followed by TKP manipulations involving ring-opening. The diazabicyclo[2.2.1]heptane structures are especially interesting as core components of biologically active products as shown in Figure 1.^{9–15}



Scheme 1. Michael addition-rearrangement strategy towards NP scaffolds




Fig 1. NPs containing the diazabicyclo[2.2.1]heptane motif

Recent reports from our group have described highly enantioselective Michael addition chemistry of various substituted TKP systems.^{16–18} The chiral TKPs are generated in highly diastereo- and enantioselective form, and are amenable to fruitful regioselective manipulation to give attractive natural product like structures.


In the present research we opted to employ novel TKP structures in which R = α -aryl and α -heteroaryl, in order to achieve the objectives shown in Scheme 1. Initially, α -aryl TKPs **1a–j** were readily prepared using

^a School of Chemistry, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

^b Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK

Electronic Supplementary Information (ESI) available: Experimental procedures, analytical data, NMR spectra and X-ray data. CCDC 1880502 and 1880503. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/x0xx00000x



Table 1. Michael additions of TKPs **1a-j** mediated by catalyst **3**


Entry	TKP	Ar	R	2 (%)	er
1	1a	Ph	Me	2a 90	92:8
2	1b	<i>p</i> -C ₆ H ₄ OMe	Me	2b 83	93:7
3	1c	<i>p</i> -C ₆ H ₄ NO ₂	Me	2c 70	95:5
4	1d	<i>p</i> -C ₆ H ₄ Br	Me	2d 88	91:9
5	1e	Furan-2-yl	Me	2e 99	94:6
6	1f	Thiophen-2-yl	Me	2f 93	94:6
7	1g	<i>o</i> -C ₆ H ₄ Br	Me	2g 88	55:44
8	1h	<i>N</i> -Methylpyrrol-2-yl	Me	2h 99	50:50
9	1i	<i>N</i> -Methylpyrrol-3-yl	Me	2i 63	77:23
10	1j	Indol-3-yl	Me	2j 91	73:27
11	1a	Ph	Et	2k 91	96:4
12	1b	<i>p</i> -C ₆ H ₄ OMe	Et	2l 75	97:3
13	1c	<i>p</i> -C ₆ H ₄ NO ₂	Et	2m 63	97:3
14	1a	Ph	Ph	2n 90	85:15
15	1b	<i>p</i> -C ₆ H ₄ OMe	Ph	2o 95	87:13
16	1c	<i>p</i> -C ₆ H ₄ NO ₂	Ph	2p 88	96:4
17	1a	Ph	H	2q 85	58:42 ^{a,b}

^a-30 °C, 12 days; ^bHPLC conducted on the acetal derivative

previously established methods.^{16,18–24} All optimisation was conducted with phenyl TKP **1a** employing methyl vinyl ketone (MVK) as the Michael acceptor (for details see ESI).²⁵ Under the optimised conditions, using the *O*-benzylated cinchona derived catalyst **3**, the Michael additions of α -aryl TKPs **1a-j** to MVK were explored and the results are shown in Table 1 (entries 1-10).

Addition products **2a-j** were isolated in good to excellent yields albeit with mixed levels of enantioselectivity. High levels of enantioselectivity were observed for substrates possessing either phenyl, *p*-substituted phenyl or unsubstituted 5-membered heterocycles (entries 1-6). Erosion of enantioselectivity appears to be the result of increased steric requirement proximal to the reacting enolate centre, e.g. with *o*-substituted aryl substrates (entries 7 and 8). This is exemplified by two *N*-Me pyrrole analogues (entries 8 and 9) in which moving the *N*-methyl group away from the reactive centre results in a significant increase in enantioselectivity. When these conditions were employed with alternative enone acceptors, varied results were obtained (entries 11-17). Enantioselectivities remained high when employing ethyl vinyl ketone (entries 11-13) while a marked reduction in selectivity was observed with the use of phenyl vinyl ketone (entries 14 and 15) with the exception of entry 16 at 96:4 er. Selectivity was vastly reduced when using acrolein as the Michael acceptor, even when the reaction was performed at lower temperature (entry 17).

Following crystallisation, the absolute configuration of adduct **2f**, generated from reaction of TKP **1f** with MVK, was determined by X-ray crystallography (Fig 2, A).²⁶

Our results are in accordance with the stereochemical model originally proposed by Deng for the dual activation and co-





Fig 2. A: Crystal structure of **2f** with ellipsoids drawn at the 50% probability level. The thiophene ring is disordered over two positions, which is the result of rotation around the C6-C15 bond, at a refined percentage occupancy ratio of 63.9(3):36.1(3), only the major position is shown for clarity. B: Model for **3**-catalysed Michael addition generating **2f**

ordination, by the catalyst, of both the nucleophile and the electrophile, and with our group's previous works (Fig 2, B).^{16,17,27}

With the Michael addition products **2** in hand, our attention turned to the removal of the oxalyl unit in an attempt to free the quaternary α -amino acid. It was envisioned that the use of a dinucleophile would achieve this goal through initial attack at the highly electrophilic C-3 carbonyl and subsequent cyclisation onto the neighbouring carbonyl.¹⁶ After investigating a range of dinucleophiles, it was found that ethanolamine removed the oxalyl component, however, the free aminoamide was not isolated. Instead, direct access to products that possess the diazabicyclo[2.2.1]heptane (**4**) core framework was achieved, Table 2.

Table 2. Rearrangement of adducts **2** to diazabicyclo[2.2.1]heptanes **4a-m**

Entry	TKP	Ar	R	4 (%)
1	2a	Ph	Me	4a 87 ^a
2	2b	<i>p</i> -C ₆ H ₄ OMe	Me	4b 51
3	2c	<i>p</i> -C ₆ H ₄ NO ₂	Me	4c 61
4	2d	<i>p</i> -C ₆ H ₄ Br	Me	4d 60
5	2e	Furan-2-yl	Me	4e 75
6	2f	Thiophen-2-yl	Me	4f 50 ^a
7	2g	<i>o</i> -C ₆ H ₄ Br	Me	4g 29
8	2h	<i>N</i> -Methylpyrrol-2-yl	Me	4h 26
9	2i	<i>N</i> -Methylpyrrol-3-yl	Me	4i 25
10	2j	Indol-3-yl	Me	4j 21
11	2k	Ph	Et	4k 50
12	2n	Ph	Ph	4l 84
13	2q	Ph	H	4m 28

^a Enantioenriched substrates retain enantiopurity




Fig 3. Crystal structure of **4a** with ellipsoids drawn at the 50% probability level

This process involves release of the TKP ring nitrogen functions from the oxalyl unit, and their convergent condensation with the ketone originating from the Michael acceptor to form an unusual bridged *N*-acyl aminal structure. Moderate to high yields were observed in most cases (entries 1-6, 11 and 12) with the exception of substrates bearing *o*-substituents (entries 7-10) and the acrolein adduct (entry 13). As expected, the conversion of enantioenriched substrates proceeded with retention of enantiopurity, as demonstrated for entries 1 and 6. The structure of **4a** was unequivocally confirmed by single crystal X-ray analysis (Fig 3).²⁸


With diazabicyclo **4a** in hand, we endeavoured to break open the newly formed cyclic aminal to reveal a quaternary 2,5-disubstituted prolinamide. Several previously described reductive ring opening conditions were examined and details can be found in the ESI.^{29–31}

Reduction of diazabicyclo **4a** with DIBAL at -78°C affords prolinamides **5a** and **5b** in a modest 6.5:1 dr with a combined yield of 57% (Scheme 2).


Interestingly, the putative intermediate iminium ion involved in the process can be isolated in the form of **6** by treatment of diazabicyclo **4a** with HCl in dioxane. Preliminary investigations have found that this also undergoes reduction to give prolinamides **5a+b** (Scheme 3).

The potential to access further natural product skeletons was investigated by *intramolecular* trapping of the iminium intermediate. Thus, diazabicyclo **9** was synthesised from TKP **7**



using our optimised methodology (Scheme 4). Treatment of **9** with HCl instigated a Pictet–Spengler reaction to yield product **10**, as a single isomer, which possesses the scaffold of the natural product harmicine.^{32,33}



Scheme 2. Reductive ring opening of **4a**



Scheme 3. Reaction pathway to prolinamides **5a+b** a) L-selectride, 1.0:1.3 dr; b) LiAlH₄, 1.5:1.0 dr



Scheme 4. Synthesis of harmicine derivative **10**

In conclusion, we have demonstrated that α -aryl TKPs can undergo asymmetric Michael additions with high selectivity and that manipulation of the TKP motif allows access to multiple products possessing NP scaffolds. We anticipate that additional biologically relevant and NP scaffolds can be accessed and investigations are currently on-going within our laboratory to unlock the further potential of the TKP motif.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We acknowledge the University of Birmingham, EPSRC and AstraZeneca for support of GP. The NMR and HPLC instruments used in this research were obtained through Birmingham Science City: Innovative uses for Advanced Materials in the Modern World (West Midlands Centre for Advanced Materials Project 2), with support from Advantage West Midlands (AWM) and part funded by the European



Regional Development Fund (ERDF). We also thank Dr Louise Male, Dr Cécile Le Duff, Dr Chi Tsang, Dr Peter Ashton and Dr Allen Bowden and the Centre for Chemical and Materials Analysis in the School of Chemistry at the University of Birmingham for analytical support.

Notes and references

- 1 D. J. Newman and G. M. Cragg, *J. Nat. Prod.*, 2016, **79**, 629–661.
- 2 A. L. Harvey, *Drug Discov. Today*, 2008, **13**, 894–901.
- 3 F. Saint-Dizier and N. S. Simpkins, *Chem. Sci.*, 2017, **8**, 3384–3389.
- 4 J. W. Reed and T. Hudlicky, *Acc. Chem. Res.*, 2015, **48**, 674–687.
- 5 P. S. Baran, T. J. Maimone and J. M. Richter, *Nature*, 2007, **446**, 404–408.
- 6 J. Shimokawa, *Tetrahedron Lett.*, 2014, **55**, 6156–6162.
- 7 S. M. Geddis, L. Carro, J. T. Hodgkinson and D. R. Spring, *Eur. J. Org. Chem.*, 2016, **35**, 5799–5802.
- 8 J. T. Njardarson, C. Gaul, D. Shan, X. Y. Huang and S. J. Danishefsky, *J. Am. Chem. Soc.*, 2004, **126**, 1038–1040.
- 9 M. Kono, Y. Saitoh, K. Shirahata, Y. Arai and S. Ishii, *J. Am. Chem. Soc.*, 1987, **109**, 7224–7225.
- 10 J. E. Saxton, *Nat. Prod. Rep.*, 1997, **14**, 559.
- 11 C. Piemontesi, Q. Wang and J. Zhu, *J. Am. Chem. Soc.*, 2016, **138**, 11148–11151.
- 12 K. B. Wang, Y. T. Di, Y. Bao, C. M. Yuan, G. Chen, D. H. Li, J. Bai, H. P. He, X. J. Hao, Y. H. Pei, Y. K. Jing, Z. L. Li and H. M. Hua, *Org. Lett.*, 2014, **16**, 4028–4031.
- 13 T. A. Van Beek, R. Verpoorte, A. B. Svendsen and R. Fokkens, *J. Nat. Prod.*, 1985, **48**, 400–423.
- 14 S. R. Rajski and R. M. Williams, *Chem. Rev.*, 1998, **98**, 2723–2796.
- 15 P. D. Bass, D. A. Gubler, T. C. Judd and R. M. Williams, *Chem. Rev.*, 2013, **113**, 6816–6863.
- 16 A. Cabanillas, C. D. Davies, L. Male and N. S. Simpkins, *Chem. Sci.*, 2015, **6**, 1350–1354.
- 17 M. Rees, N. S. Simpkins and L. Male, *Org. Lett.*, 2017, **19**, 1338–1341.
- 18 R. W. Foster, E. N. Lenz, N. S. Simpkins and D. Stead, *Chem. Eur. J.*, 2017, **23**, 8810–8813.
- 19 A. R. Katritzky, A. T. Cutler, N. Dennis, G. J. Sabongi, S. Rahimi-Rastgoo, G. W. Fischer and I. J. Fletcher, *J. Chem. Soc. Perkin Trans. 1*, 1980, 1176–1184.
- 20 K. A. Mix and R. T. Raines, *Org. Lett.*, 2015, **17**, 2358–2361.
- 21 C. R. Whitlock and M. P. Cava, *Tetrahedron Lett.*, 1994, **35**, 371–374.
- 22 S. Crooke and C. Whitlock, *Molecules*, 2012, **17**, 14841–14845.
- 23 N. A. Petasis, A. Goodman and I. A. Zavialov, *Tetrahedron*, 1997, **53**, 16463–16470.
- 24 S. R. K. Pingali, S. K. Upadhyay and B. S. Jursic, *Green Chem.*, 2011, **13**, 928–933.
- 25 ESI.
- 26 The CIF for the crystal structure of 2f has been deposited with the CCDC and given the deposition number, CCDC 1880502.
- 27 H. Li, Y. Wang, L. Tang, F. Wu, X. Liu, C. Guo, B. M. Foxman and L. Deng, *Angew. Chem. Int. Ed.*, 2005, **44**, 105–108.
- 28 The CIF for the crystal structure of 4a has been deposited with the CCDC and given the deposition number, CCDC 1880503.
- 29 M. Sannigrahi, P. Pinto, T. M. Chan, N. Y. Shih and F. George Njoroge, *Tetrahedron Lett.*, 2006, **47**, 4877–4880.
- 30 M. Kasai, M. Kono, S. Ikeda, N. Yoda and N. Hirayama, *J. Org. Chem.*, 1992, **57**, 7296–7299.
- 31 Y. Zhang, L. Zheng, F. Yang, Z. Zhang, Q. Dang and X. Bai, *Tetrahedron*, 2015, **71**, 1930–1939.
- 32 I. T. Raheem, P. S. Thiara, E. A. Peterson and E. N. Jacobsen, *J. Am. Chem. Soc.*, 2007, **129**, 13404–13405.
- 33 T.-S. Kam and K.-M. Sim, *Phytochemistry*, 1998, **47**, 145–147.

